Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease

Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease

ObjectivesGrowing evidence argues for a relationship between liver and bone metabolisms. Sclerostin is a secreted glycoprotein and could antagonize osteoblast-mediated bone formation. Previous studies indicated that circulating sclerostin levels may be associated with metabolic parameters with incon...

Full description

Bibliographic Details
Main Authors:	Fangli Zhou, Yan Wang, Yujue Li, Mengjia Tang, Shan Wan, Haoming Tian, Xiang Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-08-01
Series:	Frontiers in Endocrinology
Subjects:	sclerostin NAFLD fatty liver index bone metabolism triglyceride
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2021.707505/full

Similar Items

Patophysiology of nonalcoholic fatty liver disease
by: Ewa Krzewicka-Romaniuk, et al.
Published: (2019-09-01)

Patophysiology of nonalcoholic fatty liver disease
by: Ewa Krzewicka-Romaniuk, et al.
Published: (2019-09-01)

Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico
by: Yvonne N. Flores, et al.
Published: (2021-10-01)

Drug discovery of sclerostin inhibitors
by: Sifan Yu, et al.
Published: (2022-05-01)

Comparison of liver enzymes and sonological grading in nonalcoholic fatty liver
by: Bishnu Jwarchan, et al.
Published: (2020-03-01)

Sclerostin Modulation Holds Promise for Dental Indications
by: Mohamed G. Hassan, et al.
Published: (2018-11-01)

Triglyceride-Glucose Index for Early Prediction of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of 121,975 Individuals
by: Azizullah Beran, et al.
Published: (2022-05-01)

Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases
by: Stéphanie Fabre, et al.
Published: (2020-10-01)

Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease
by: Min-Sun Kwak, et al.
Published: (2012-12-01)

Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones
by: Jialiang S. Wang, et al.
Published: (2021-03-01)

Nonalcoholic fatty liver disease (NAFLD) among older adults
by: Panyavee Pitisuttithum, et al.
Published: (2022-12-01)

Identification of Sclerostin as a Putative New Myokine Involved in the Muscle-to-Bone Crosstalk
by: Maria Sara Magarò, et al.
Published: (2021-01-01)

Association between serum ferritin and uric acid levels and nonalcoholic fatty liver disease in the Chinese population
by: Fangli Zhou, et al.
Published: (2023-10-01)

Sclerostin Blood Levels Before and After Kidney Transplantation
by: Marco Bonani, et al.
Published: (2014-07-01)

Serum sclerostin in rheumatoid-induced osteoporosis
by: Ola Gharbia, et al.
Published: (2020-07-01)

Is sclerostin antibody an effective agent for alveolar bone regeneration in animal models? A scoping review
by: Venkitachalam Ramanarayanan, et al.
Published: (2022-12-01)

Plasma sclerostin level in multiple myeloma: Correlations with disease features and international staging system
by: Noor Hasan Baiee, et al.
Published: (2022-01-01)

What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease
by: Giovanni Targher
Published: (2020-10-01)

Correlation between Body Mass Index and Nonalcoholic Fatty Liver Disease
by: Abdulhadi Liebi Alrubaie, et al.
Published: (2022-05-01)

Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease
by: Ioanna Aggeletopoulou, et al.
Published: (2023-08-01)

Decreased Serum Level of Sclerostin in Older Adults with Sarcopenia
by: Seong Hee Ahn, et al.
Published: (2022-06-01)

The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease
by: Ning Gao, et al.
Published: (2022-11-01)

Positive and Negative Regulators of Sclerostin Expression
by: Rina Iwamoto, et al.
Published: (2022-04-01)

Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Magdalena Mazurek, et al.
Published: (2023-02-01)

Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis
by: Timothy Dreyer, et al.
Published: (2021-07-01)

Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options
by: Daniela Maria Tanase, et al.
Published: (2020-08-01)

Nonalcoholic Fatty Liver Disease and Endocrine Axes—A Scoping Review
by: Madalena Von-Hafe, et al.
Published: (2022-03-01)

The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease
by: Umair Iqbal, et al.
Published: (2019-03-01)

Serum sclerostin in vascular calcification in CKD: a meta-analysis
by: Yan Lin, et al.
Published: (2023-12-01)

The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts
by: Karina E. Pigeaud, et al.
Published: (2023-04-01)

Associations between Nonalcoholic Fatty Liver Disease and Histopathological Features of Patients with Adenocarcinoma of Colon in Dharmais National Cancer Hospital, National Cancer Center, Indonesia
by: Goldy Natanael, et al.
Published: (2022-04-01)

Prediction of Cardiovascular Risk Using Nonalcoholic Fatty Liver Disease Scoring Systems
by: Ye-Na Kweon, et al.
Published: (2021-07-01)

Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia
by: Ghada M. A. Ajabnoor, et al.
Published: (2023-01-01)

Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease
by: Anna Jeznach-Steinhagen, et al.
Published: (2019-05-01)

Sclerostin as a novel marker of bone turnover in athletes
by: A Zagrodna, et al.
Published: (2016-02-01)

Antitumor Effect of Sclerostin against Osteosarcoma
by: Hirokazu Ideta, et al.
Published: (2021-11-01)

Metabolic Syndrome and Nonalcoholic Fatty Liver Disease: Nutritional Approach for Prevention
by: Zamzam Paknahad, et al.
Published: (2013-11-01)

Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus
by: Ryan D. Ross, et al.
Published: (2020-06-01)

Incidence of Metabolic Syndrome and Its Risk Factors in Elderly with Nonalcoholic Fatty Liver Disease
by: Lin FA, et al.
Published: (2023-09-01)

Serum Sclerostin Level Is Negatively Associated with Bone Mineral Density in Hemodialysis Patients
by: Jing-Wun Lu, et al.
Published: (2022-03-01)